DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)

A Non-Interventional, Post-Authorisation Study to Assess Adverse Events and Drug Utilisation Among Chronic Kidney Disease Patients Treated With DYNEPO

This is a post-authorisation safety study to assess the incidence and severity of all pre-defined cardiovascular events in patients treated with DYNEPO, as well as to detect & describe less common adverse drug reactions, and to summarise DYNEPO drug utilisation.

Inclusion Criteria:

• Adult patients must have established Chronic Kidney Disease (CKD) and be willing and able to provide written informed consent.
• Patients must already be receiving DYNEPO treatment at time of study entry.
• Patients who are likely to receive DYNEPO for at least 1 year.

Exclusion Criteria:

• Known intolerance to EPO of any of its excipients
• Known of suspected Pure Red Cell Aplasia (PRCA)